For health care professionals
Seattle Cancer Care Alliance (SCCA) is a nationally recognized treatment center that provides advanced therapies and clinical trials for cancers and other blood disorders. SCCA unites the doctors and technology from Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children's and provides a variety of resources for community doctors and other healthcare professionals.
News from our blog
Over the last decade, Seattle Cancer Care Alliance (SCCA) has prepared oncologists for board review examinations by providing a Comprehensive Oncology Review Course. This course offers the latest advances in standards of care, from nationally renowned experts across the spectrum of hematology and oncology.
Seattle Cancer Care Alliance (SCCA) treats more MCL patients than almost any other center in the Pacific Northwest region and offers one of the nation’s most robust portfolios of standard treatments and clinical trials, in partnership with Fred Hutchinson Cancer Research Center and University of Washington Medical Center (UWMC)
SCCA is moving to Epic as its singular electronic health record platform. Epic is the predominant electronic health record (EHR) at health systems throughout the Puget Sound area. Patients, staff and providers in our region are familiar with Epic and its associated tools (e.g. MyChart and Care Everywhere).
SCCA’s all-female colorectal surgery team pioneers a multi-disciplinary approach: Drs. Mukta Krane, Sarah Atkinson, Michelle Cowan and Joy Chen.
Podcasts
- Seeking a breakthrough in DLBCL combination therapies with Dr. Ryan Lynch
- Understanding treatment options for standard- and high-risk CLL with Dr. Mazyar Shadman
- New data on risks and treatment for patients with cancer and COVID-19
- SCCA Offers Appleby Procedure
- SCCA is Committed to Bring World-Class Cancer Treatment to Patients in Their Own Communities
Publications
- Journal for ImmunoTherapy of Cancer: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Cancer Cell Journal: Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade
GI ASCO Posters and Papers
- A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302)
- Phase II trial of the CDK4/6 inhibitor abemaciclib in patients (pts) with advanced and refractory well‐differentiated gastroenteropancreatic neuroendocrine tumors (GEP NETs)
GU ASCO Papers and Posters
- TraceIT: A Prospective Pilot Study of a Temporary Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy
- TROPiCS-04: Study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy
- A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer
- Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens
- Use of 18F-fluciclovine PET/CT (FluPET) for prostate cancer (PC): Initial results from a prospective registry at a tertiary academic center
- HHV-8 positive clinically advanced castrate-resistant prostate cancer (mCRPC): A potentially distinct molecular subset
- Approaches to immune checkpoint inhibitor (ICI) maintenance therapy in metastatic urothelial cancer (mUC): A qualitative analysis of oncology providers in the United States
- The impact of telemedicine on patient-reported outcomes in urologic oncology
Clinical trials
- A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
- Investigator: Sylvia M. Lee, MD
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)
- Investigator: David G. Maloney, MD, PhD
- A Study of CART-PSMA-TGFßRDN in Patients With Metastatic Castration Resistant Prostate Cancer
- Investigator: Dr. Michael Schweizer
- Subscribe to clinical trial portfolios
- Skin: SLMskin@seattlecca.org
- GU & Renal: SLMgu@seattlecca.org
- Heme and Heme Malignancies: subscribe by signing up for Oncology Insights
Physician talks
- Immunotherapy for Advanced Prostate Cancer; Progress and new hope
- Petros Grivas, MD
- Management of Multiple Myeloma: Updates from ASH 2020
- Andrew Cowan, MD
- Northwest Melanoma Symposium: A Virtual Event for Patients
- Saturday, April 10, 2021
- David Byrd, MD; Evan Hall, MD, MPhil; Ata Moshiri, MD, MPH; Teresa Kim, MD; Shailender Bhatia, MD
Resources
- New videos
- Imaging Request Form
New providers
